Zyprexa investigation possible
Executive Summary
Lilly antipsychotic Zyprexa (risperidone) may be next mental health product subject to an U.S. Office of Personnel Management investigation. "Several pharmaceutical companies have received subpoenas from government agencies with respect to a variety of products, including a number of neuroscience products," 1Lilly's 8-K, filed with the Securities & Exchange Commission March 9, says. "It is possible that other Lilly products, including Zyprexa, could become subject to investigation." OPM has issued requests related to Wyeth's Effexor, Forest's Celexa and Johnson & Johnson's Risperdal (2"The Pink Sheet" Feb. 2, 2004, In Brief)...